XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues [Abstract]        
Revenue $ 93,973 $ 46,435 $ 205,295 $ 131,498
Operating expenses        
Cost of revenue 18,157 16,667 53,135 54,035
Research and development 23,669 24,163 72,006 79,761
Sales and marketing 23,470 20,551 70,090 63,184
General and administrative 17,959 17,258 53,144 54,750
Amortization of intangible assets 428 428 1,270 1,275
Impairment of long-lived assets 0 0 0 7,205 [1]
Total operating expenses 83,683 79,067 249,645 260,210
Income (loss) from operations 10,290 (32,632) (44,350) (128,712)
Interest and other income, net 2,226 3,474 7,296 11,462
Interest expense (2,971) (2,939) (8,824) (8,628)
Net income (loss) 9,545 (32,097) (45,878) (125,878)
Add: Net loss (income) attributable to noncontrolling interest 1 26 (42) 78
Net income (loss) attributable to Adaptive Biotechnologies Corporation $ 9,546 $ (32,071) $ (45,920) $ (125,800)
Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ 0.06 $ (0.22) $ (0.3) $ (0.86)
Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ 0.06 $ (0.22) $ (0.3) $ (0.86)
Weighted-average shares used in computing net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 152,432,307 147,516,398 151,248,398 146,908,234
Weighted-average shares used in computing net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 163,162,107 147,516,398 151,248,398 146,908,234
[1] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expense.